Alpha lactalbumin is a whey protein, found among other places, in mothers milk. It has recently been in the news as the primary protein used in the search for a cure for breast cancer.

For the last eight years, Dr. Vincent Tuohy, at the Cleveland Clinic, has been searching for a vacine for breast cancer. Dr. Tuohy discovered that mice injected with the vaccine, based on Alpha lactalbumin, did not develop breast tumors, while 100 percent of the mice that were not vacinated, had breast tumors.

The vacine also seems to inhibit the growth of pre-existing tumors.

In an interview he also states that "There's nothing fancy about it. We're vaccinating against something that isn't there unless you have tumors, so it shouldn't harm you. And it should kill the tumors,".

The main part of the vaccine, a protein called Alpha lactalbumin found in lactating breasts, is also found in breast tumors, but not in healthy breasts. It is suggested that women who are finished breast feeding, would recieve the vaccine thus boosting their own immune systems and supplying the means to kill off cancerous cells while not damaging healthy ones.

"We think that breast cancer is a completely preventable disease in the same way that polio is completely preventable," Dr. Tuohy says.

This sort of research gives hope to anyone who has, or knows of anyone with breast cancer. To say nothing of outright prevention. In 2009, The American cancer society estimates that there was 192,370 new cases of invasive breast cancer and 40,170 deaths from breast cancer.

(c) 2010 Alphalactalbumin.com

Use of this article is forbidden without express permission from the author.

The Breast Cancer Research Foundation Announces New Board Members
The Breast Cancer Research Foundation announced today the addition of three new members to its Board of Directors. William P. Lauder, Abbe Raven and Maria Baum will join the foundation's esteemed board, ...Read More...

Breast cancer prevention drug provides benefit long after women stop taking it
KANSAS CITY, Kan. Breast cancer is the most common cancer in women. Yet fewer than one out of 10 women at higher risk take medication for prevention. New research finds one medicine continues to lower the chances of cancer long after women stop taking it. Missy Schaffer lost her mother and grandmother to breast [ ]Read More...

Six diagnosed after cancer recall
Six women previously given the all-clear are diagnosed with breast cancer after a review of assessments made by Oxfordshire's Breast Screening Service.Read More...

Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment
Molecular diagnostics company Genetic Technologies Limited announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms improves the predictive accuracy ...Read More...

Breast cancer drugs in second rejection
Manufacturers need to price more realistically, says James JoplingRead More...

No Link Between Migraine, Breast Cancer Risk, Study Says
Title: No Link Between Migraine, Breast Cancer Risk, Study Says Category: Health News Created: 12/12/2014 12:00:00 AM Last Editorial Review: 12/15/2014 12:00:00 AMRead More...

Longer Course of Radiation Treatment for Breast Cancer Patients Means More Need Social Security Disability Insurance
Two-thirds of breast cancer patients who've had surgery endure six to seven weeks of radiation therapy even though studies suggest that a three week course of higher-dose radiation is just as effective, ...Read More...

Canberra women have higher risk of being diagnosed with breast cancer
The ACT had the country's highest incidence rate for breast cancer in women between 2005 and 2009, a new report reveals.Read More...

Genomic Health's Oncotype DX Positive in Multiple Studies - Analyst Blog
Developer of genomic-based clinical laboratory services, Genomic Health Inc. (GHDX) recently announced positive feedback from the clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS.Read More...

Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use ...
Regulatory News:Read More...